



# Actinium Pharmaceuticals Highlights Presence at Upcoming Society of Nuclear Medicine and Molecular Imaging Annual Meeting

- *Society of Nuclear Medicine and Molecular Imaging to be held June 10 – 14, 2017 in Denver, Colorado*
- *Actinium to conduct webinar to provide an update on its Pivotal Phase 3 drug candidate, Iomab-B, on Monday June 12, 2017 at 8 AM EST*
- *Clinical Advisor, Dr. Joseph Jurcic, to present data from Actimab-A on Tuesday, June 13, 2017*
- *Company to host Investigator Meeting focused on nuclear medicine physicians interested in learning about Iomab-B and the SIERRA trial*

NEW YORK, June 08, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the Company's planned activities at the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting that is being held in Denver, Colorado June 10 – 14, 2017. The SNMMI annual meeting brings together leading nuclear medicine physicians, scientists and technologists from leading medical and academic centers.

Dr. Mark Berger, Chief Medical Officer of Actinium Pharmaceuticals said, "Nuclear medicine physicians are vital to the administration of our targeted radioimmunotherapies. We value the important contributions these physicians make to the field, our clinical trials and ultimately to the administration of these important therapies to patients. We very much look forward to the SNMMI annual meeting where we will have the opportunity to further educate physicians from existing and prospective clinical trial sites on the points of differentiation of our drug candidates Iomab-B, Actimab-A and Actimab-M as well as our alpha particle technology platform."

Representatives from Actinium's clinical development, corporate development and executive teams will attend the SNMMI annual meeting. Actinium will be hosting an investigator meeting on Sunday, June 11, 2017 for nuclear medicine physicians interested in learning more about Iomab-B and the SIERRA Trial. On Tuesday, June 13, 2017, Dr. Joseph Jurcic, Director of Hematologic Malignancies and Professor of Clinical Medicine at Columbia

University Medical Center and Chair of Actinium's Clinical Advisory Board will present data from the Company's Actimab-A program. In addition, Actinium will be conducting a webinar on Monday, June 12, 2017 at 8 AM EST. The webinar will provide update on the Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B and will feature Dr. Rajneesh Nath, a SIERRA trial investigator who is the Director of Bone Marrow Transplant and the Acute Leukemia Program at Banner MD Anderson Cancer Center. Participants from Actinium will include Dr. Mark Berger, Chief Medical Officer, Steven Price, Vice President of Clinical and Commercial Development and Sandesh Seth, Executive Chairman.

Participants can register and view the webinar via the following link:

<https://onecast.thinkpragmatic.com/ses/DID8Ygo2vc2bdaaDIWg97g~~>

Sandesh Seth, Executive Chairman of Actinium said, "This year's SNMMI annual meeting should prove to be very exciting and rewarding given the advancements we have made since last year's meeting. Since last year's meeting we have initiated and advanced the pivotal SIERRA trial for Iomab-B, progressed into a Phase 2 trial for Actimab-A and expanded our alpha particle program with the launch of the Actimab-M clinical trial in multiple myeloma. The team is very much looking forward to updating conference attendees on our accomplishments and learning about recent advances in the field that we can incorporate in our radioimmunotherapy development efforts."

### **About Actinium Pharmaceuticals, Inc.**

Actinium Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. In addition, Actinium is developing Actimab-M, which is being studied in patients with relapsed or refractory multiple myeloma in a Phase 1 clinical trial. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceuticals is based in New York, NY. To learn more about Actinium Pharmaceuticals, please visit [www.actiniumpharma.com](http://www.actiniumpharma.com) and to follow @ActiniumPharma on Twitter please visit, [www.twitter.com/actiniumpharma](http://www.twitter.com/actiniumpharma).

### **Forward-Looking Statements for Actinium Pharmaceuticals, Inc.**

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.

Steve O'Loughlin  
Vice President, Finance and Corporate Development  
[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)



Source: Actinium Pharmaceuticals